Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 235

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 19
Chunk 235
---
 104           Cover Page Interactive                                                                                                                                                                                

  Filed herewith.  

  Management contract or  

SIGNATURES

The registrant hereby certifies that it meets
all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Annual Report
on Form 20-F filed on its behalf.

                              CLEARMIND                                   
  Date: January 22, 2025      By:                /s/                      
                                                 Dr.                      
                                                 Chief Executive Officer  

CLEARMIND
MEDICINE INC.

Consolidated
Financial Statements

(Expressed
in United States Dollars)

F-1

CLEARMIND
MEDICINE INC.

Index
of Financial Statements

As
of October 31, 2024

                                                                            Page  
  Reports of Independent Registered Public Accounting Firms                 F-3   
  (Firm Name: Brightman Almagor Zohar & Co / PCAOB ID No. 1197)             F-3   
  Consolidated Statements of Financial Position                             F-4   
  Consolidated Statements of Operations and Comprehensive Loss              F-5   
  Consolidated Statements of Changes in Shareholders’ Equity (Deficit)      F-6   
  Consolidated Statements of Cash Flows                                     F-7   
  Notes to the Consolidated Financial Statements                            F-8   

F-2

REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the shareholders
and the Board of Directors of Clearmind Medicine Inc.

Opinion
on the Financial Statements

We have audited
the accompanying consolidated statements of financial position of Clearmind Medicine Inc. and its subsidiaries (the “ Company”)
as of October 31, 2024, and 2023, the related consolidated statements of operations and comprehensive loss, changes in shareholders’
equity (deficit) and cash flows for each of the three years in the period ended October 31, 2024, and the related notes (collectively referred
to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the
financial position of the Company as of October 31, 2024 and 2023, and the results of its operations and its cash flows for each of the
three years in the period ended October 31, 2024, in conformity with International Financial Reporting Standards as issued by the International
Accounting Standards Board.

Going
Concern

The accompanying